Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573754 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
A Phase 2 study of Porphyria Cutanea Tarda, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01573754 is a Phase 2 study of Porphyria Cutanea Tarda that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01573754, a Phase 2 study of Porphyria Cutanea Tarda, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of time to remission. Patients with well documented PCT are assigned to treatment by randomization if specific criteria are met. All patients are followed until remission - defined as achieving a normal plasma porphyrin concentration.
Conditions Studied
Interventions
- PROCEDURE Phlebotomy
- DRUG Hydroxychloroquine
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-03-21 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573754
The ClinicalTrials.gov registry entry for NCT01573754 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Porphyria Cutanea Tarda appearing as the primary indexed condition, and to 2 interventions - of which Phlebotomy is the first listed.
NCT01573754 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01573754 about?
NCT01573754 is a clinical study titled "Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda". Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of time to remission. Patients with...
What is the current status of trial NCT01573754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2006-03-21. Estimated completion is 2021-07-06.
What conditions does trial NCT01573754 study?
This clinical trial studies the following conditions: Porphyria Cutanea Tarda.
What interventions are being tested in trial NCT01573754?
The interventions under investigation include: Phlebotomy (PROCEDURE), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01573754?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01573754 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Porphyria Cutanea Tarda
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.